Ketamine intranasal - Roivant Sciences
Alternative Names: RVT-701Latest Information Update: 08 Jan 2022
At a glance
- Originator Roivant Sciences
- Class Amines; Analgesics; Antidepressants; Antihyperglycaemics; Antiparkinsonians; Anxiolytics; Behavioural disorder therapies; Chlorobenzenes; Cyclohexanes; General anaesthetics; Ketones; Mood stabilisers; Neuroprotectants; Neuropsychotherapeutics; Obesity therapies; Small molecules
- Mechanism of Action NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Autistic disorder
Most Recent Events
- 21 Jan 2019 Discontinued - Phase-I for Autistic disorder (In adolescents, In children, In adults) in USA (Intranasal) (Roivant Sciences pipeline, January 2019)
- 29 Jun 2018 Chemical structure information added
- 07 May 2018 Roivant Sciences completes a phase I trial in Autistic disorder (In children, In adolescents, In adults ) in USA (Intranasal) (NCT02611921)